drugset / Trial / NCT06580223

Aspirin or Rivaroxaban Thromboprophylaxis for Patients With Multiple Myeloma

NCT06580223

RandomizedParallel-groupOpen-labelPrevention

Summary

The aim of this study is to evaluate the efficacy and safety of aspirin and rivaroxaban in thromboprophylaxis in Chinese MM patients at high risk for MM-associated VTE.

Timeline

Start
2025-09-01
Primary completion
2027-09-01
Completion
2027-09-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Aspirin Small molecule 100 mg Oral
Subject Rivaroxaban Other / unclassified 10 mg Oral